Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Abbott |
---|---|
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00237887 |
A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis
Condition | Intervention | Phase |
---|---|---|
Psoriasis |
Drug: adalimumab |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | M03-656 |
Study First Received: | October 7, 2005 |
Last Updated: | August 28, 2007 |
ClinicalTrials.gov Identifier: | NCT00237887 |
Health Authority: | United States: Food and Drug Administration |
Psoriasis adalimumab |
Skin Diseases Psoriasis Adalimumab Skin Diseases, Papulosquamous |
Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Pharmacologic Actions |